Welcome to our dedicated page for Viatris Ord Shs news (Ticker: VTRS), a resource for investors and traders seeking the latest updates and insights on Viatris Ord Shs stock.
Viatris Inc. (NASDAQ: VTRS) is a global healthcare leader formed through the merger of Upjohn and Mylan, delivering essential medicines across 165+ countries. This page provides centralized access to official corporate announcements and market-moving developments.
Investors and analysts will find timely updates including earnings reports, regulatory milestones, and strategic partnerships. Track the company’s progress in generic pharmaceuticals, biosimilars, and therapeutic innovations through verified press releases.
Our curated news feed serves as a reliable resource for understanding Viatris’ operational decisions, product pipeline advancements, and global healthcare initiatives. Bookmark this page to stay informed about one of the pharmaceutical industry’s most diversified companies.
Viatris Inc. (NASDAQ: VTRS) has won three categories at the 2022 LMG Life Sciences Americas Awards, including U.S. In-House Legal Team of the Year for Intellectual Property Litigation. This recognition follows significant victories in patent litigation, particularly for generic Tecfidera and Lantus, along with establishing new law on venue for such cases. Viatris has consistently achieved recognition for its legal team and corporate responsibility, emphasizing its commitment to delivering affordable medicines globally.
Viatris Inc. (NASDAQ: VTRS) and Kindeva Drug Delivery have achieved a pivotal court victory, with the U.S. District Court for the Northern District of West Virginia declaring AstraZeneca's Symbicort® patent (U.S. Patent No. 10,166,247) invalid. The ruling was based on two grounds: lack of written description and lack of enablement. This decision enables Viatris to progress with FDA-approved generic versions, enhancing patient access to essential medications. This marks the fourth invalidation of AstraZeneca's Symbicort patents, supporting Viatris's commitment to providing affordable healthcare solutions.
Viatris Inc. (NASDAQ: VTRS) announced plans to create an ophthalmology franchise by acquiring Oyster Point Pharma and Famy Life Sciences for $700-$750 million in cash. The acquisitions aim to close in Q1 2023, expecting to add over $1 billion in net sales and $500 million in adjusted EBITDA by 2028. The company also anticipates that these transactions, along with a stock repurchase program, will be accretive to adjusted EPS for 2023. Viatris reaffirmed a pre-tax proceeds target of up to $9 billion from the Biocon transaction and non-core asset divestitures.
Viatris reaffirms its 2022 guidance for total revenues, adjusted EBITDA, and free cash flow, reporting solid operating momentum despite foreign exchange challenges and inflation impacts. Total revenues stand at $4.08 billion, with U.S. GAAP net earnings of $354 million and adjusted EBITDA of $1.50 billion. The company generated $869 million in net cash from operating activities and $765 million in free cash flow. Year-to-date, Viatris has paid down $2.1 billion of debt ahead of schedule and declared a quarterly dividend of $0.12 per share.
Viatris Inc. (NASDAQ: VTRS) will announce its financial results for Q3 2022 on November 7, 2022, at 8:30 a.m. ET. Key executives, including Executive Chairman Robert J. Coury and CEO Michael Goettler, will host a webcast reviewing the quarterly results and an update regarding the February 28 Investor Event. Investors can access the live call via investor.viatris.com or by calling provided numbers. Viatris, established in November 2020, focuses on providing global healthcare solutions through its extensive portfolio of approved products.
Viatris Inc. (NASDAQ: VTRS) will participate in the BofA Global Research Global Healthcare Conference on September 15, 2022, in London. The event will feature a fireside chat with CEO Michael Goettler, President Rajiv Malik, and CFO Sanjeev Narula, scheduled for 4:45 p.m. BST / 11:45 a.m. ET. A live webcast will be available at investor.viatris.com, along with an archived version post-event. Viatris, formed in November 2020, aims to enhance global health by providing access to over 1,400 medicines.
Viatris reported total revenues of $4.12 billion with U.S. GAAP net earnings at $314 million and adjusted EBITDA of $1.48 billion. The company generated U.S. GAAP net cash provided by operating activities of $803 million and free cash flow of $719 million in the first half of 2022. Despite facing foreign exchange headwinds, it reaffirms guidance for adjusted EBITDA and free cash flow, while revising total revenues guidance to reflect currency impacts. A quarterly dividend of $0.12 per share was declared, and the company paid down $1.5 billion in debt with a target of $2 billion for the full year.
Viatris Inc. (NASDAQ: VTRS) will announce its second quarter 2022 financial results on August 8 before U.S. market opening. A live webcast will be held at 8:30 a.m. ET on the same day to discuss the results. Viatris, formed in November 2020, offers over 1,400 approved molecules across various therapeutic areas and operates globally with around 37,000 employees. The company's mission is to provide access to high-quality medicines, leveraging its extensive portfolio and global healthcare capabilities.
Viatris Inc. (NASDAQ: VTRS) will participate in the Goldman Sachs 43rd Annual Global Healthcare Conference on June 14, 2022, in Rancho Palos Verdes, CA. CEO Michael Goettler, President Rajiv Malik, and CFO Sanjeev Narula will engage in a fireside chat at 1:20 p.m. PT. A live webcast of the event will be available on investor.viatris.com and an archived version will follow.
Viatris, formed in November 2020, operates globally with a portfolio of over 1,400 approved molecules across diverse therapeutic areas.
FAQ
What is the current stock price of Viatris Ord Shs (VTRS)?
What is the market cap of Viatris Ord Shs (VTRS)?
